MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells

A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling

(2012) Lucy Liu et al.   CANCER BIOLOGY & THERAPY

The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia

(2012) H. J. Lee et al.   CLINICAL CANCER RESEARCH

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

(2012) Apostolos Kontzias et al.   CURRENT OPINION IN PHARMACOLOGY

Spirooxindole Derivative SOID-8 Induces Apoptosis Associated with Inhibition of JAK2/STAT3 Signaling in Melanoma Cells

(2012) Yan Tian et al.   PLoS One

Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition

(2012) Rami Komrokji et al.   Expert Review of Hematology

6-Bromoindirubin-3'-Oxime Inhibits JAK/STAT3 Signaling and Induces Apoptosis of Human Melanoma Cells

(2011) L. Liu et al.   CANCER RESEARCH

Targeting Src family kinases in anti-cancer therapies: turning promise into triumph

(2011) Siyuan Zhang et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches

(2010) Stephen Y. Lai et al.   DRUG RESISTANCE UPDATES

5,5′-Substituted Indirubin-3′-oxime Derivatives as Potent Cyclin-Dependent Kinase Inhibitors with Anticancer Activity

(2010) Soo-Jeong Choi et al.   JOURNAL OF MEDICINAL CHEMISTRY

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

Sustained Src Inhibition Results in Signal Transducer and Activator of Transcription 3 (STAT3) Activation and Cancer Cell Survival via Altered Janus-Activated Kinase-STAT3 Binding

(2009) B. Sen et al.   CANCER RESEARCH

17-Hydroxy-jolkinolide B Inhibits Signal Transducers and Activators of Transcription 3 Signaling by Covalently Cross-Linking Janus Kinases and Induces Apoptosis of Human Cancer Cells

(2009) Y. Wang et al.   CANCER RESEARCH

Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer

(2009) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies

(2009) Jacqueline Sayyah et al.   Current Oncology Reports

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Triterpenoid CDDO-Methyl Ester Inhibits the Janus-Activated Kinase-1 (JAK1)->Signal Transducer and Activator of Transcription-3 (STAT3) Pathway by Direct Inhibition of JAK1 and STAT3

(2008) R. Ahmad et al.   CANCER RESEARCH

Therapeutic targeting of Janus kinases

(2008) Marko Pesu et al.   IMMUNOLOGICAL REVIEWS

Soluble 3′,6-Substituted Indirubins with Enhanced Selectivity toward Glycogen Synthase Kinase -3 Alter Circadian Period

(2008) Konstantina Vougogiannopoulou et al.   JOURNAL OF MEDICINAL CHEMISTRY